Retatrutide
GLP-1 / Metabolic research-only
Mechanism
No mechanism summary on file.
Identification
Safety
Not FDA-approved. In Eli Lilly Phase 3 development as of 2026 (GLP-1 / GIP / glucagon triagonist). Genuine API supply is constrained because the molecule is not yet in commercial pharma channels — Finnrick flagged a counterfeit Retatrutide sample at Peptide Sciences in November 2025. Quality variation across vendors is high; treat any research-market retatrutide with particular skepticism.
Vendors selling Retatrutide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptide Partners | — | — | — | 65 |
| Nuscience Peptides | — | — | — | 60 |
| Elite Research USA | — | — | — | 53 |
| Pure Peptides | — | — | — | 53 |
| Skye Peptides | — | — | — | 53 |
| Peptide Sciences | — | — | — | 26 |
| Paradigm Peptides | — | — | — | 0 |
Research
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Giblin K, Kaplan LM, Somers VK, et al. · Diabetes Obes Metab (2026) ·
source → Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Coskun T, Wu Q, Schloot NC, et al. · Lancet Diabetes Endocrinol (2025) · rct
source → What is the pipeline for future medications for obesity?
Melson E, Ashraf U, Papamargaritis D, et al. · Int J Obes (Lond) (2025) · review
source → Emerging pharmacotherapies for obesity: A systematic review.
Kokkorakis M, Chakhtoura M, Rhayem C, et al. · Pharmacol Rev (2025) · review
source → Retatrutide-A Game Changer in Obesity Pharmacotherapy.
Katsi V, Koutsopoulos G, Fragoulis C, et al. · Biomolecules (2025) · review
source → The power of three: Retatrutide's role in modern obesity and diabetes therapy.
Abdul-Rahman T, Roy P, Ahmed FK, et al. · Eur J Pharmacol (2024) · review
source → Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Sanyal AJ, Kaplan LM, Frias JP, et al. · Nat Med (2024) · rct
source → Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
Drucker DJ · Diabetes Care (2024) · review
source → Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, Frias J, Jastreboff AM, et al. · Lancet (2023) · rct
source → Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, et al. · N Engl J Med (2023) · rct
source →